AbbVie (ABBV)
(Delayed Data from NYSE)
$195.45 USD
-1.37 (-0.70%)
Updated Oct 3, 2024 04:00 PM ET
After-Market: $195.38 -0.07 (-0.04%) 5:18 PM ET
3-Hold of 5 3
C Value D Growth D Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$195.45 USD
-1.37 (-0.70%)
Updated Oct 3, 2024 04:00 PM ET
After-Market: $195.38 -0.07 (-0.04%) 5:18 PM ET
3-Hold of 5 3
C Value D Growth D Momentum D VGM
Zacks News
AbbVie Seeks US and EU Nods for Rinvoq for Psoriatic Arthritis
by Zacks Equity Research
AbbVie (ABBV) files applications to the FDA and the EMA seeking approval for a new indication of Rinvoq, active psoriatic arthritis. The drug is already marketed to treat rheumatoid arthritis.
Improve Your Retirement Income with These 3 Top-Ranked Dividend Stocks - June 02, 2020
by Zacks Equity Research
The traditional approaches to retirement planning are longer covering all expenses in nest egg years. So what can retirees do? Thankfully, there are alternative investments that provide steady, higher-rate income streams to replace dwindling bond yields.
The Zacks Analyst Blog Highlights: Tencent, Abbvie and Reckitt Benckiser
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Tencent, Abbvie and Reckitt Benckiser
3 Strong Pharmaceutical and Biotech Stocks to Buy for Coronavirus Immunity
by Benjamin Rains
Let's dive into three large-cap pharmaceutical and biotech stocks that appear set to grow during the pandemic-induced downturn and the eventual recovery...
AbbVie Gets FDA Nod for Oriahnn to Control Menstrual Bleeding
by Zacks Equity Research
The FDA approves AbbVie's (ABBV) Oriahnn oral capsule for checking heavy menstrual bleeding related to uterine fibroids in pre-menopausal women. It will be sold in US markets by June-end.
Positives and Negatives: Global Week Ahead
by John Blank
The growing divergence between an increasingly dire economic landscape and a roaring U.S. stock market will be on display on Friday when May non-farm payroll employment data is reported.
Lilly's Cyramza Gets FDA Approval for First-Line Lung Cancer
by Zacks Equity Research
FDA approves Lilly's (LLY) Cyramza as a combination regimen for metastatic EGFR-mutated non-small cell lung cancer. Cyramza is now approved for six indications to treat four different types of cancers.
Why Is AbbVie (ABBV) Up 12.7% Since Last Earnings Report?
by Zacks Equity Research
AbbVie (ABBV) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Powerful Proof Anyone Can Invest for an Early Retirement - May 29, 2020
by Zacks Equity Research
Accomplishing the financial cushion to retire early is a fantasy for most, but bringing that fantasy to reality is not as difficult as it sounds. If you are willing to make some serious lifestyle adjustments, it can be achievable.
Ironwood to Halt MD-7246 Development After Study Failure
by Zacks Equity Research
Ironwood's (IRWD) pipeline candidate, MD-7246 fails to meet primary endpoint in a phase II study evaluating it in patients with irritable bowel syndrome with diarrhea.
Should You Invest in the VanEck Vectors Pharmaceutical ETF (PPH)?
by Zacks Equity Research
Sector ETF report for PPH
Sanofi's Dupixent Gets FDA Approval for Eczema in Children
by Zacks.com
Sanofi (SNY) secures an FDA nod for Dupixent as the first biologic medicine for children aged from six to 11 years with moderate-to-severe atopic dermatitis.
argenx Up on Positive Data from Pivotal Efgartigimod Study
by Zacks Equity Research
argenx's (ARGX) lead pipeline candidate, efgartigimod, meets primary endpoint in a pivotal study evaluating it in myasthenia gravis. A BLA is likely to be filed by the end of 2020.
How Trading Your Own Retirement Can Fleece Your Financial Future - May 27, 2020
by Zacks Equity Research
From understanding your risk tolerance to maintaining emotional control, achieving your retirement goals takes a much different investing approach than regular stock trading.
3 Top Dividend Stocks to Maximize Your Retirement Income - May 27, 2020
by Zacks Equity Research
The traditional approaches to retirement planning are longer covering all expenses in nest egg years. So what can retirees do? Thankfully, there are alternative investments that provide steady, higher-rate income streams to replace dwindling bond yields.
Top Ranked Income Stocks to Buy for May 27th
by Zacks Equity Research
Here are four stocks with buy rank and strong income characteristics for investors to consider today, May 27th.
This is Why AbbVie (ABBV) is a Great Dividend Stock
by Zacks Equity Research
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does AbbVie (ABBV) have what it takes? Let's find out.
Zacks Value Trader Highlights: AbbVie, B&G Foods, H&R Block, Microsoft and Apple
by Zacks Equity Research
Zacks Value Trader Highlights: AbbVie, B&G Foods, H&R Block, Microsoft and Apple
Is AbbVie (ABBV) Stock a Solid Choice Right Now?
by Zacks Equity Research
AbbVie (ABBV) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Top Ranked Income Stocks to Buy for May 22nd
by Zacks Equity Research
Here are four stocks with buy rank and strong income characteristics for investors to consider today, May 22nd.
This Book Changed Warren Buffett's Life
by Tracey Ryniec
With the coronavirus crisis throwing investors for a loop, it's time to consult with the father of value investing, Benjamin Graham.
Simple Secrets Anyone Can Use to Reach Early Retirement - May 21, 2020
by Zacks Equity Research
Achieving the financial freedom to retire early is a dream for most, but making that dream a reality isn't as tricky as it sounds. If you are willing to make some serious lifestyle changes and sacrifices, it can be possible.
3 Top Dividend Stocks to Maximize Your Retirement Income - May 20, 2020
by Zacks Equity Research
The traditional approaches to retirement planning are longer covering all expenses in nest egg years. So what can retirees do? Thankfully, there are alternative investments that provide steady, higher-rate income streams to replace dwindling bond yields.
Dr. Reddy's (RDY) Q4 Earnings Increase Y/Y, Revenues Beat
by Zacks Equity Research
Dr. Reddy's (RDY) fourth-quarter earnings and sales increase year over year.
AbbVie, Interactive, Inphi, Chegg and ServiceNow highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
AbbVie, Interactive, Inphi, Chegg and ServiceNow highlighted as Zacks Bull and Bear of the Day